All In Biotech

Drug Trial Radar · NCT04579666

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Last checked: Nov 19, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 249 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

249

Actual

Start

Sep 30, 2020

Primary completion

Mar 31, 2023

Study completion Jul 13, 2023

Sponsor

Lead sponsor
Apellis Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)

Conditions

  • Amyotrophic Lateral Sclerosis
  • Motor Neuron Disease

Interventions

  • Pegcetacoplan (APL-2)Drug

    Complement (C3) Inhibitor

  • PlaceboOther

    Sterile solution of equal volume to active arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RTP: Combined Assessment of Function and Survival (CAFS) Rank Score (Joint-Rank Score) at Week 52Time frame: Week 52
  2. RTP: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From first dose of study drug (Day 1) up to 56 days post last dose of study drug, approximately 60 weeks
  3. OLP: Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse EventsTime frame: From first dose of study drug (Week 52) up to 56 days post last dose of study drug, approximately 60 weeks
  4. RTP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale (C-SSRS) up to Week 52Time frame: Baseline (Day 1) up to Week 52
  5. OLP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale up to Week 104Time frame: From Baseline (Week 52) up to Week 104

Locations

60 sites in 14 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of Colorado

    Aurora, Colorado

  • University of South Florida

    Tampa, Florida

  • Augusta University

    Augusta, Georgia

  • Indiana University

    Indianapolis, Indiana

  • Johns Hopkins

    Baltimore, Maryland

  • The Berman Center

    Minneapolis, Minnesota

  • Hospital for Special Surgery

    New York, New York

  • Austin Neuromuscular Center

    Austin, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • Brain and Mind Centre

    Camperdown, New South Wales, Australia

  • Central Coast Neurosciences Research

    Erina, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Gold Coast University Hospital

    Southport, Queensland, Australia

  • Nueor-Immunology Clinical Researh Education and Support Service (N-CRESS), Austin Health

    Heidelberg, Victoria, Australia

  • AZ Sint-Lucas & Volkskliniek

    Ghent, Belgium

  • Universitaire Ziekenhuizen Leuven (UZ Leuven)

    Leuven, Belgium

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia

  • FORBELI s.r.o.

    Prague, Czechia

  • Hopital Pellegrin

    Bordeaux, France

  • Hôpital Neurologique Pierre Wertheimer

    Bron, France

  • CHU Gabriel Montpied

    Clermont-Ferrand, France

  • Hôpital Roger Salengro

    Lille, France

  • CHU de Limoges Dupuytren 1

    Limoges, France

  • CHU de Nice Hôpital Pasteur

    Nice, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Medizinische Hochschule Hannover Klinik für Neurologie

    Hanover, Germany

  • Universitätsklinikum Jena

    Jena, Germany

  • Universitätsmedizin Rostock, Klinik und Poliklinik für Neurologie

    Rostock, Germany

  • University of Ulm

    Ulm, Germany

  • Beaumont Hospital

    Dublin, Ireland

  • Ospedale Niguarda - Nemo Clinical Center - Fondazione Serena Onlus

    Milan, Italy

  • Ospedale Civile S. Agostino Estense di Modena, Azienda Ospedaliero Universitaria di Modena

    Modena, Italy

  • AOUP "P. Giaccone"

    Palermo, Italy

  • Azienda Ospedaliera Universitaria di Torino - Città della Salute e della Scienza di Torino

    Torino, Italy

  • National Hospital Organization Higashinagoya National Hospital

    Aichi, Japan

  • National Hospital Organization Omuta National Hospital

    Fukuoka, Japan

  • National Hospital Organization Asahikawa Medical Center

    Hokkaido, Japan

  • National Hospital Organization Hyogo-Chuo National Hospital

    Hyōgo, Japan

  • National Hospital Organization Iou National Hospital

    Ishikawa, Japan

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.